Abstract
In the last 25 years, neuroscientists in search of a cure for Alzheimer’s disease (AD) have devoted their efforts to developing therapeutic strategies targeting the amyloid-β (Aβ) peptide. However, considering the questionable results of the clinical trials so far, it is vital to examine other targets and therapeutic approaches to restore cognitive function in AD patients and to slow down disease progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Molecular therapy : the journal of the American Society of Gene Therapy
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
